MedTrace Logo

Immunotherapy in Lung Cancer: Treatment After IO Cessation.

NCT04465942 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2021-08-23

No results posted yet for this study

Summary

Immunotherapy is now a standard of care for first-line and eventually salvage therapy in patients with stage IV NSCLC and as adjuvant after RT-CT for stage III NSCLC.

The aim of the study is determining the therapeutic landscape and the reason for immunotherapy cessation.

Conditions

  • Carcinoma, Non-Small-Cell Lung
  • Immunotherapy

Interventions

DRUG

(chemo)immunotherapy

Patients are receiving immunotherapy or chemoimmunotherapy as a standard of care

Sponsors & Collaborators

  • European Lung Cancer Working Party

    lead OTHER

Principal Investigators

  • Thierry Berghmans, MD, PhD · ELCWP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-26
Primary Completion
2024-06-30
Completion
2025-06-30

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04465942 on ClinicalTrials.gov